skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The next generation: etravirine in the treatment of HIV-1 infection in adults refractory to other antiretrovirals

Review

(1868) Views  (831) Full article downloads

Authors: R Chris Rathbun, Michelle D Liedtke

Published Date July 2010 Volume 2010:2 Pages 91 - 102
DOI: http://dx.doi.org/10.2147/VAAT.S6413

R Chris Rathbun, Michelle D Liedtke

Department of Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, USA

Abstract: Etravirine is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) that is approved for the treatment of adult human immunodeficiency virus (HIV)-infected patients with documented or suspected resistance to first-generation NNRTIs. Etravirine has a flexible molecular structure that allows it to retain its activity against mutant HIV strains that exhibit resistance to first-generation agents. It is evident that 3 or more etravirine resistance-associated mutations are typically necessary before clinical resistance to etravirine. Safety and efficacy of etravirine are established in antiretroviral treatment-experienced patients in combination with antiretroviral regimens that contain darunavir/ritonavir. In phase III studies, cutaneous reactions occurred in 19% of treated patients and are the most commonly observed adverse event. The typical manifestation is the development of a maculopapular rash within the first few weeks of etravirine therapy. Resolution commonly occurs within 1–2 weeks on continued therapy. Rare cases of severe skin reactions (<0.1%) have been reported. Etravirine is hepatically metabolized by cytochrome P450 (CYP) 3A4, CYP2C9, and CYP2C19. Drug interactions with some antiretrovirals (eg, unboosted protease inhibitors and fosamprenavir/ritonavir) and medications for other comorbidities (eg, atorvastatin and clarithromycin) have been reported and may require dosage adjustment for the coadministered drug or selection of alternative therapy in some instances. Administration of etravirine with potent inducers of CYP450 is not recommended due to the potential for subtherapeutic etravirine concentrations. In this article, the pharmacology, efficacy, safety, and tolerability of etravirine in adult treatment-experienced patients with HIV-1 infection are reviewed. Medical literature was identified by MEDLINE and EMBASE searches (1966 to February 2010) using the search terms “etravirine”, “TMC125”, and “NNRTI”.

Keywords: etravirine, TMC125, non-nucleotide reverse transcriptase inhibitor, antiretrovival, HIV







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Profile of etravirine for the treatment of HIV infection
A method for evaluating antiviral drug susceptibility of Epstein-Barr virus
Tapentadol immediate release: a new treatment option for acute pain management
Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
Resistance patterns and genetic variations in patients with hepatitis C virus: emerging role of telaprevir
An update on small molecule inhibitors of the HCV NS5B polymerase: effects on RNA synthesis in vitro and in cultured cells, and potential resistance in viral quasispecies
Differential susceptibility of HIV strains to innate immune factors in human cervical-vaginal secretions
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio